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Drug resistance in malarial parasites has become a major obstacle in the control of the disease. Strategies
are urgently needed to control the development of resistance and to possibly reverse existing resistance. One
key element required to reverse malaria drug resistance is for the parasites to “pay” a biological “cost” or
suffer a loss of fitness when acquiring resistance to antimalarial drugs. Such a situation would be a disad-
vantage to the resistant parasites in the absence of drug pressure. We compared here the relative fitness of
atovaquone-resistant Plasmodium falciparum K1 clones with single and double base mutations in their cyto-
chrome b genes to their parent clones during erythrocytic stages in the absence of drug pressure. We found that
the double amino acid mutation (M133I and G280D) is associated with a 5 to 9% loss of fitness and that the
single amino acid change of M133I did not result in any detectable loss of fitness. Molecular modeling of the
interaction of P. falciparum cytochrome b with ubiquinone led to the prediction that a loss of fitness of the
malaria parasites would result from the G280D mutation due to its close proximity to the putative ubiquinone-
binding site. This appears to have resulted in a weakening of the cytochrome b-ubiquinone complex, thereby
causing the electron transport chain to become less efficient. Our results suggest that the prevalence of
resistant parasites may decrease after the drug usage is discontinued.
During the past 3 decades, Plasmodium falciparum has de-
veloped resistance to almost every commonly available anti-
malarial drug, including chloroquine, pyrimethamine, cy-
cloguanil, and sulfadoxine. The rapid spread of these resistant
parasites has dramatically affected the successful treatment of
patients; some drugs are now almost useless in many parts of
the world.
To slow the development of resistance and prolong the ef-
fectiveness of antimalarial drugs, it is generally recommended
that combinations of synergetic antimalarials should be used
(37). It has also been suggested that the usage of a particular
drug should be stopped when a certain level of treatment
failure is observed (World Health Organization Expert Com-
mittee on Malaria, 1998 [http://mosquito.who.int/docs
/ecr206.htm.]). Removal of the selection pressure exerted by
the drug may enable the population of susceptible parasites to
reestablish itself and gradually replace resistant parasites.
However, for this strategy to be effective, three essential ele-
ments are required: (i) a proportion of parasites that are still
susceptible to the drug (that is, they do not carry the mutation);
(ii) drug-resistant parasites that are less fit compared to the
susceptible wild-type parasites in the absence of drug pressure;
and (iii) transmission levels that are high enough to result in
some multiple infections.
Resistance to antimalarial drugs can result from mutations
to a single target locus in the parasites (e.g., pyrimethamine
resistance [9]) or from alterations to multiple loci (e.g., chlo-
roquine resistance [12, 24]), or it can result from upregulation
or duplication of genes associated with the influx or efflux of
the antimalarial drugs (14). In many organisms, mutations that
confer resistance to drugs clearly provide the organism with a
survival advantage under these drug pressures. However, ge-
netic mutations resulting in drug resistance are often associ-
ated with a loss of fitness to the organism due to alterations to
functionally or structurally important regions of the target mol-
ecules (6, 11, 35, 38). This loss of fitness causes resistant or-
ganisms to become disadvantaged relative to the wild-type
parasites when the drug pressure is withdrawn.
In the case of malaria, the relative fitness of the resistant
parasites in the absence of drug pressure is unclear. Rosario et
al. (26) reported that in mice infected with a mixture of chlo-
roquine-resistant and -susceptible Plasmodium chabaudi, a
higher proportion of chloroquine-resistant P. chabaudi sur-
vived to recrudesce between days 26 and 36 (i.e., 26 and 36
generations), suggesting a selection advantage to chloroquine-
resistant parasites. However, in the same study, experiments
on pyrimethamine-resistant parasites did not show a clear ad-
vantage for resistant over sensitive parasites. Shinondo et al.
(31) reported that pyrimethanime-resistant and -sensitive Plas-
modium berghei grew similarly during blood stages but that the
resistant parasites proceeded through sporogonic development
more slowly than the susceptible parasites. In P. falciparum,
studies were performed to demonstrate that chloroquine-resis-
tant parasites have transmission advantages over sensitive par-
asites, as indicated by higher parasitemia levels in asymptom-
atic carriers (36) and higher gametocyte prevalence and
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density (16, 25). However, none of these studies measure the
relative fitness of resistant parasites to the sensitive parasites
because of the continuous usage of chloroquine in the com-
munities.
In this study, we compared the relative fitness of atova-
quone-resistant K1 clones, with double (M133I, G280D) and
single (M133I) base mutations in the cytochrome b gene, to
their parent clones without these mutations. We found that the
double amino acid mutation (M133I, G280D) resulted in ap-
proximately a 5 to 9% loss in fitness compared to the wild type.
However, the single-amino-acid change M133I did not result in
any detectable loss in fitness. We propose that the observed
loss of fitness results from the reduced binding of ubiquinone
to cytochrome b caused by the G280D mutation occurring
close to a putative atovaquone-binding and ubiquinone-bind-
ing site.
MATERIALS AND METHODS
Parasites. (i) Wild-type parasites. P. falciparum K1-P, K1-B, K1-C, K1-D, and
K1-E are wild-type sibling clones of K1 originating from five separate parasite-
containing wells produced by a limiting dilution procedure (19). These parasites
are considered clonal since only 7% of the wells contained parasites after the
limiting dilution procedure.
(ii) Mutant parasites. P. falciparum ATV-M1, ATV-M4-1, and ATV-M4-2 are
mutant clones selected by exposing K1-P to atovaquone (19). ATV-M1 is a clone
of resistant parasites that contains a single-base mutation in the parasite cyto-
chrome b gene resulting in a M133I change at the amino acid level. ATV-M4-1
and ATV-M4-2 are two sibling clones of resistant parasites that each contains
two single-base mutations in the cytochrome b gene, resulting in amino acid
changes at M133I and G280D.
In vitro cultivation of P. falciparum. Parasites were maintained in vitro under
conditions modified from those described by Trager and Jensen (34).
Growth competition experiments. The wild-type and mutant clones of para-
sites were synchronized by using 5% sorbitol for the ring stage (20) and 63%
Percoll for the schizont stage (28). The number of infected erythrocytes in each
culture was determined by multiplying the number of erythrocytes by the per-
centage of parasitemia. Two growth competition experiments were carried out as
follows. In experiment 1, K1-P and K1-E were each mixed with either ATV-M4-1
or ATV-M4-2 at a ratio of ca. 1:1 of wild-type to mutant parasites. The wild-type
and mutant parasites were also cultured in separate flasks as controls. All cul-
tures were maintained in duplicate for 108 days, after which they were cryopre-
served (8). In an extension of experiment 1, cryopreserved wild-type and mutant
control parasites from experiment 1 were thawed, remixed at a 1:1 ratio, and
cultured for a further 60 days. In experiment 2, K1-P, -B, -C, -D, and -E were
each mixed with ATV-M1 at a ratio of ca. 1:1. Again, the wild-type and mutant
parasites were cultured in separate flasks as controls. All cultures were main-
tained in duplicate for 105 days.
DNA extraction. A fraction of the parasite cultures were collected every 20
days and parasite genomic DNA extracted by using a method previously de-
scribed (7). The extracted DNA were resuspended in 100 l of TE (10 mM Tris
pH 8.0 and 1 mM EDTA, pH 8.0) and stored at 20°C. The DNA was diluted
100-fold for use in the competitive PCR.
Quantitative PCR. A competitive PCR was performed to quantify the ratio of
wild-type to mutant parasites. A pair of primers, cytb1 (5-CTC TAT TAA TTT
AGT TAA AGC ACA C-3) and cytb4 (5-ATT TTT AAT GCT GTA TCA
TAC CCT-3), were designed to amplify a fragment at the 5 end of cytochrome
b flanking the M133I mutation. A forward primer cytb-s (5-TTG CAC CCC
AAT AAC TC-3) was designed to anneal to the wild-type cytochrome b gene
with its 3 end matching ATG (M133), and a reverse primer cytb-m1 (5-TAC
CAT GGG GTC AAA TA-3) was designed to anneal to the mutant type
cytochrome b with its 3 base matching ATA (I133). PCR was performed with 2
mM Mg2Cl, 0.2 mM concentrations of each deoxynucleoside triphosphate (Pro-
mega, Madison, Wis.), 75 ng of each of the four primers, 1.25 U of Ampli-
TaqGold (PE Applied Biosystems), and 1 l of diluted DNA. The reaction
mixture was initially heated at 93°C for 10 min and then underwent a touchdown
cycling program. The cycling conditions were as follows: 20 cycles at 93°C for
50 s, an initial 65°C decreasing by 1°C per cycle for 50 s, and 70°C for 50 s,
followed by 20 cycles of 93°C for 50 s, 45°C for 50 s, and 70°C for 50 s.
Quantitation. PCR products were separated on a 2% agarose gel and visual-
ized on a UV transilluminator. Gel images were captured by using a Kodak
Digital Science EDAS 120 system, and net intensities for wild-type and mutant
cytochrome b bands were measured by using Kodak ID analysis software. A
series of controls were made by mixing genomic DNA from wild-type parasites
with that of mutant parasites at 1:1, 3:1, 10:1, 30:1, and 100:1 ratios. The controls
were amplified in parallel with the samples. After each PCR, a standard curve
was generated from the controls and the ratio of wild-type to mutant parasites in
a sample was determined based on the standard curve.
DNA sequencing. Full-length cytochrome b was amplified with the primers
cytb1 and cytb2 (19) and then sequenced from both orientations.
DNA fingerprinting. Parasite genomic DNA collected from each sample at the
beginning and end of the growth competition experiments was digested with
restriction enzyme AccI, electrophoresed on a 1% agarose gel, and transferred to
Hybond-N membranes. A digoxigenin (DIG)-labeled 7H8/6-specific probe
(21) was generated by PCR with the M13 forward and reverse primers and
DIG-labeled dUTPs (Roche Diagnostics, Pty., Ltd., Castle Hill, Australia). The
probe was hybridized to the membrane overnight at 65°C. The membranes were
washed three times with 2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate)–0.1% sodium dodecyl sulfate at 65°C. An anti-DIG antibody alkaline
phosphatase conjugate (Roche) was bound to the probe and detected by using
CDP-Star chemiluminescence substrate (Roche) exposed to Kodak Biomax
Light-1 film (Amersham Pharmacia Biotech, Pty., Ltd., Castle Hill, Australia).
Chromosomal mapping. Parasite chromosomal DNA was prepared in 0.8%
low-melting-point agarose blocks (18) and separated by pulsed-field gel electro-
phoresis (29) in a 0.8% agarose gel by using the CHEF-DR III system (Bio-Rad
Laboratories, Hercules, Calif.). Electrophoresis was performed for 24 h at 3
V/cm, with a switch time of 270 to 500 s, and then 25 h at 2.4 V/cm and 500 to
900 s, followed by 20 h at 1.8 V/cm and 1,200 s, and then finally 18 h at 1.8V/cm
and 1,600 s (M. Tchavtchitch, Queensland Institute of Medical Research [un-
published data]). The electrophoresis buffer was maintained at a constant 14°C
and changed every 24 h. The separated chromosomes were visualized by staining
with ethidium bromide. The gel was transferred to a Hybond-Nmembrane and
hybridized with a DIG-labeled 7H8/6 probe.
Degree of loss of fitness. The loss of fitness of the mutant parasites relative to
the wild type was determined by assuming that the ratio of mutant to wild-type
parasites is defined as follows: mutant/wild-type ratio  1:(starting ratio/[1 
loss]n), where “loss” is the theoretical loss of fitness of the mutant (as a propor-
tion), and n is the number of generations since the start of the experiment.
Least-squares linear regression of the form ln(experimental ratio)  c  mn
was used to estimate the loss of fitness, where m  ln(1  loss) and c 
ln(starting ratio).
Molecular modeling. A homology model of P. falciparum CYT b (19) was used
to investigate the possible effect of mutations in cytochrome b to the ubiquinone
binding site in the same molecule. The ubiquinone molecule was docked to the
CYT b model based on predictions by Bartoschek et al. (3) and Crofts et al. (10)
and by using the program GOLD (17). The resulting complex and the M133I and
M133I-G280D mutated complexes were energy minimized by using the program
Discover.
Molecular simulations. The models of the wild-type, M133I, and M133I-
G280D mutant cytochrome b P. falciparum models were simulated in vacuo at
300K by using the GROMACS 3.0 package (4, 22) and the GROMOS 43a1 force
field (30) in a 0.5-ns interval with an integration step size of 1 fs. Chemical bonds
were restricted only at the start by using the SETTLE algorithm (27) and were
represented by a harmonic potential throughout the simulation. Position re-
straints were imposed on all atoms except hydrogens with a force constant of 1
MJ/mol  nm2. Temperature coupling was carried out by using the Berendsen
temperature-coupling scheme (5). Short- and long-range electrostatics were sim-
ulated by using a Coulomb type interaction with a distance to neighbors of 1 nm,
a van der Waals cutoff of 1.4 nm, an electrostatic cutoff of 1.4 nm, and a dielectric
constant of 1.
RESULTS
Quantitative PCR and standard curve. The quantitative
PCR generated three specific bands: band F, amplified with
primers 1 and 4; band W, amplified with primers 1 and S; and
band M, amplified with primers 4 and M1 (Fig. 1). The ratio of
band intensity between bands W and M was measured for the
control samples in which wild-type and mutant parasite DNAs











were mixed at 1:1, 3:1, 10:1, 30:1, and 100:1. A log linear
regression curve was calculated and used as the standard curve.
ATV-M4 has a slower growth rate than the wild-type para-
sites. Two sibling clones of ATV-M4 were each mixed with two
sibling clones of K1 (K1-P and K1-E) and cultured continu-
ously for 108 days. The starting ratios of wild-type to mutant
parasites were between 0.40 and 0.90, and these ratios in-
creased steadily to beween 18 and 66 by day 108 (Fig. 2A and
B; Table 1). Figure 1 shows an example of the change in the
ratio of wild-type to mutant type occurring in the K1-P and
ATV-M4-1 mixture as measured by quantitative PCR. During
the culture period, the wild-type band (W) increased in inten-
sity, while the mutant band decreased in intensity. No change
was seen in the wild-type and mutant parasites cultured alone.
DNA sequencing confirmed the changes observed by PCR.
At the beginning of the experiment, sequencing of the DNA
from the mixed cultures clearly showed mixed nucleotide sig-
nals at the bases where the mutations were located; at the end
of the experiment only the wild-type nucleotides were seen in
these positions (data not shown).
The relatively slow growth rate in ATV-M4 is stable. Para-
sites that were frozen after 108 days of culture were thawed,
remixed in a 1:1 ratio, and cultivated in vitro for an additional
60 days. The same trend observed in the first 108 days of
culture was seen in the change of the wild-type/mutant ratio
during this 60-day period (data not shown).
The difference in growth rates was predicted to be 5 to 9%.
For the first 108-day experiment, the growth rate of the
ATV-M4 clone was predicted to be between 4.97 to 8.67%
slower than that of the wild-type K1-P and K1-E (Table 1),
averaging at 5.97%. There is agreement in the predicted ratio
of growth rates between the replicates and across replicates
and also in the experimental ratio (Fig. 2).
DNA fingerprinting with a stable probe 7H8/6 showed that
all of the clones were identical in banding patterns at both the
start and the end of the experiment (data not shown). These
results indicate that there was no cross-contamination of the
cultures from other sources and that no major genomic rear-
rangements occurred in these parasite clones during culturing.
ATV-M1 has the same growth rate as the wild-type parent
FIG. 1. Gel electrophoresis of PCR product showing the change of the wild-type/mutant ratio over time in duplicate in K1-P and ATV-M4-1
mixtures (A), K1-E and ATV-M1 mixtures (B), and wild type or mutant parasite alone (C). In the control panels, lanes A, B, C, D, and E represents
the wild-type parasite DNA mixed with mutant parasite DNA at 1:1, 3:1, 10:1, 30:1, and 100:1, respectively. Bands: F, full-length product; W, wild
type; M, mutant.











parasites. ATV-M1 was mixed with five sibling wild-type K1
clones separately and cultured for 105 days in vitro. As shown
in Fig. 2C, the starting ratio of wild-type to ATV-M1 parasites
varied from 2.59 to 4.28. The ratios of K1-B, -C, -D, and -E to
ATV-M1 fluctuated during the time of culture but did not
change substantially from the start to the end of the experi-
ment (Fig. 2C; Table 2), i.e., ATV-M1 grew at approximately
the same rate as K1-B, -C, -D, and -E (1.7 to 0.1% faster;
Table 2). The ratio of the growth rate of K1-P to ATV-M1
changed dramatically during the culture. By day 29 the K1-P to
ATV-M1 ratio was higher than 100:1, and the mutant type was
not detectable from day 45 onward (Fig. 2C). The estimated
difference in the growth rate of K1-P compared to ATV-M1
was between 29.1 and 36.4% higher (Fig. 2C, Table 2). To
investigate whether significant genomic or chromosomal rear-
rangement occurred in this K1-P clone during the culture pe-
riod, DNA fingerprinting and chromosomal mapping were per-
formed. No genetic or chromosomal rearrangement was
detected in this clone of the parasite during the period of
culturing.
The slower growth rate is associated with a change in the
ubiquinone-binding site. Molecular modeling revealed that the
G280D change in ATV-M4 caused an alteration of the orien-
tation of a putative ubiquinone-binding residue, L271(Fig. 3).
After energy minimization of the ubiquinone-cytochrome b
complex containing the G280D mutation, steric interference
and an altered electrostatic environment was observed in the
putative ubiquinone-binding site (Fig. 3). In contrast, the
M133I mutation was relatively conserved both chemically and
structurally and caused little variation when minimized (Fig.
3).
Molecular simulations of the M133I, M133I-G280D, and
wild-type cytochrome b-modeled proteins without ubiquinone
resulted in disruption to the structure when G280D was intro-
duced. These results support the notion that the G280D mu-FIG. 2. Change of wild-type/mutant ratio. (A) K1-P and ATV-M4
mixtures (PM4-1-1/2 and PM4-2-1/2); (B) K1-E and ATV-M4 mixtures
(EM4-1-1/2 and EM4-2-1/2); (C) K1-P, -B, -C, -D, -E and ATV-M1
mixtures (PM1-1/2, BM1-1/2, CM1-1/2, DM1-1/2, and EM1-1/2). The-
oretical curves were produced by fitting a regression model to the
grouped data for the four K1-P and ATV-M4 mixtures (R2  0.929, P
 0.001) (A) and the two groups of K1-E and ATV-M4 mixtures
(theoretical A, R2  0.918, P  0.001 for EM4-1-1 and EM4-1-2 data;
theoretical B, R2  0.969, P  0.001 for EM4-2-1 and EM4-2-2) (B).
TABLE 1. Total change in the wild type (K1-P and K1-E) to
mutant parasite (ATV-M4-1 and ATV-M4-2) ratios and estimated





Predicted % difference in
growth rate (95% CI)a
K1-P/M4-1-1 22.64 4.99 (3.5–6.5)
K1-P/M4-1-2 26.94 5.27 (3.8–6.7)
K1-P/M4-2-1 39.61 5.55 (3.1–8.0)
K1-P/M4-2-2 28.53 5.53 (3.7–7.3)
K1-E/M4-1-1 26.32 4.97 (2.4–7.4)
K1-E/M4-1-2 17.97 4.97 (3.6–6.3)
K1-E/M4-2-1 165.58 8.67 (6.3–11.0)
K1-E/M4-2-2 86.83 7.35 (5.7–8.9)
a CI, confidence interval.
TABLE 2. Total change in the wild-type (K1-P, -B, -C, -D, and -E)/
mutant parasite (ATV-M1) ratios and estimated differences in









K1-B/M1-1 1.30 0.1 (0.6 to 0.4)
K1-B/M1-2 1.02 0.3 (1.0 to 0.4)
K1-C/M1-1 0.19 1.2 (1.8 to 0.6)
K1-C/M1-2 0.19 1.7 (2.9 to 0.6)
K1-D/M1-1 1.05 0.1 (0.8 to 0.6)
K1-D/M1-2 1.51 0.1 (0.9 to 1.1)
K1-E/M1-1 0.73 0.3 (0.9 to 0.4)
K1-E/M1-2 0.78 0.2 (0.9 to 0.5)
a CI, confidence interval. , Confidence intervals were not calculated since
there are only three datum points.











tation is responsible for the loss binding of ubiquinone in the
putative ubiquinone-binding site (Fig. 3).
DISCUSSION
Drug resistance in malarial parasites often results from mu-
tations in a gene that then expresses a protein with a lower
binding capacity for a particular drug or the duplication or
upregulation of a gene that leads to an increased expression of
a particular protein. In each case, changes in a single locus or
in multiple loci may be involved in resistance. In this study, we
studied the loss of fitness associated with mutations that oc-
curred in a single locus, the cytochrome b locus of the parasite
genome.
The atovaquone-resistant mutants ATV-M1 and ATV-M4
were selected by exposing the parent parasite clone to atova-
quone and then cloning the resistant parasites. The selection
and cloning of the resistant parasites was carried out over ca.
110 days, i.e., the mutant parasite clones used in the fitness
experiment were 55 generation lineages from the parent par-
asite clone. Thus, genomic differences between the mutant and
parent parasites were limited. The resistant mutations oc-
curred in the cytochrome b gene of the mitochondria genome
in the mutant parasites. When the mutant parasites (ATV-M4)
were mixed with parent parasites at ca. 1:1 ratio and then
cultured in the same flask and under the same conditions, the
proportion of the ATV-M4 parasites (two amino acid changes)
decreased steadily over time. Similar changes were observed in
replicates of each parent-mutant mixture. Therefore, this
change in proportion did not result from clonal variation but
was due to a relatively slower growth rate of the mutant par-
asite ATV-M4 compared to the wild-type K1-P and K1-E. The
results demonstrate that there is a loss of fitness associated
with the ATV-M4 mutant parasites.
In contrast, for ATV-M1 that has a single amino acid
change, the proportion of wild-type to mutant parasites did not
change over time in four of five mixtures, suggesting that there
was no loss of fitness associated with ATV-M1 since the mu-
tant parasites had the same growth rates as four of the five
wild-type parasites. In the fifth mixture, in which the parent
clone K1-P was mixed with ATV-M1 and a rapid takeover of
K1-P was observed, it is likely that uncharacterized changes
occurred in this K1-P genome that allowed the parasite to grow
faster than ATV-M1, since a similar change was not observed
in the four other mixtures with ATV-M1. This change may
have occurred in the period between the thawing of this K1-P
and the start of this particular experiment since K1-P was the
only parasite clone that had been substantially cultured (	100
days) prior to the start of experiment, and a different vial of
K1-P used in the ATV-M4 mixtures did not exhibit the same
behavior. Chromosome mapping and DNA fingerprinting of
the parasites at the start and the end of culture failed to detect
any rearrangement in the genome and no extra mutations were
found in the cytochrome b gene of the parasite, suggesting that
the change or changes in this particular K1-P are likely to be
mutations that have occurred in a locus outside of cytochrome
b.
The loss of fitness in ATV-M4 was calculated to be between
5 and 9% (averaging 5.97%). This estimate demonstrates the
biological disadvantage sustained by the mutant parasites at
the erythrocytic stages. Whether the mutations also alter par-
asite transmission abilities, such as the production and viability
of gametocytes, the fertilization process, and development in
mosquitoes, requires further investigation.
Atovaquone is widely used in combination with proguanil
under the trade name of Malarone. Atovaquone acts against
malaria parasites by inhibiting mitochondrial electron trans-
port (15) and collapsing mitochondrial membrane potential
(32). Due to its structural similarity to ubiquinone, it is postu-
lated that the action is achieved by binding to cytochrome b as
a ubiquinone analogue (Fig. 4). Therefore, mutations at the
atovaquone-binding site may affect the parasite’s ability to bind
ubiquinone. Molecular modeling predicted that the loss of
fitness in ATV-M4 had resulted from the G280D mutation
interfering with the binding of parasite cytochrome b to ubiqui-
none. The G280D mutation was predicted to occur in close
vicinity to the putative ubiquinone-binding site, causing a loss
of the hydrophobic interaction between L271 and ubiquinone.
This change was not fatal to the parasites and explains the
reduced efficiency of the parasites electron transport chain
mechanism. In contrast, the M133I change was relatively con-
served and, although M133 is putatively involved directly in
FIG. 3. (A) Ribbon representation of wild-type cytochrome b
bound to ubiquinone. Amino acid side chains, ubiquinone, and heme
are represented in stick form, and the Fe center of heme is represented
in CPK form. (B) Ribbon representation of G280D-M133I cytochrome
b bound to ubiquinone after energy minimization. The G280D muta-
tion affects L271 and hence the ubiquinone-binding site.











binding to ubiquinone, the change had little effect on the
binding. In the presence of atovaquone, the loss of fitness was
outweighed by the parasite’s ability to resist the drug pressure.
However, when drug pressure was withdrawn, the resistant
parasites were disadvantaged due to an impaired electron
transport chain. The resistance profile of the mutants provides
additional support for this differential effect caused by these
mutations. M133I, which is predicted to have a moderate effect
on the atovaquone binding, conferred a 25-fold resistance to
atovaquone, while the combination of M133I and G280D, pre-
dicted to significantly affect the drug binding site, conferred an
800-fold reduction in susceptibility to atovaquone (19).
This is the first study showing a loss of fitness associated with
drug-resistant P. falciparum. The outcome has significant im-
plications in the formulation of drug policies in geographic
areas where malaria is endemic, especially in countries such as
Africa, where malaria transmission is high. Our results suggest
that it is important to monitor the prevalence of resistance and
that the usage of a drug should be stopped before the preva-
lence of resistance reaches a high level. These may allow the
prevalence of resistance to drugs to be reduced over a number
of years. In the case of single locus resistance, the speed of this
decrease in resistance depends first of all on the prevalence of
resistance at the time drug usage is stopped. For instance, if
drug usage is ceased when resistance prevalence is only 50%,
the reversal will occur in a shorter time than if the prevalence
has reached 90%. Second, the speed of the decrease in the
prevalence of drug resistance depends on the frequency of
mixed infections in the human host since the decreased fitness
will only be manifested in competition with wild-type parasites.
Generally, the frequency of mixed infections will increase as
the transmission intensity increases. Thus, the reversal of drug
resistance will be more difficult in populations in low-transmis-
sion areas where infections are predominantly clonal (1, 2, 13).
Finally, the degree of loss of fitness associated with the devel-
opment of resistance will determine the speed of the decline.
This degree of loss may vary between various drugs. It should
be noted that, although the loss was stable in vitro culture
system for a period of ca. 170 days, it is possible that the
mutant parasites may develop compensatory mutations after a
number of generations. These compensatory mutations might
decrease the degree of loss or even totally cancel the deficit
they carried.
Although our study only examined loss of fitness associated
with atovaquone-resistant parasites, our results highlight the
possibility of decreasing the prevalence of resistance to other
drugs. In fact, decreases in the prevalence of resistance to
chloroquine have been observed in several countries where
drug usage has officially ceased for a number of years. A study
conducted in Hainan, China, showed that the prevalence of
chloroquine-resistant P. falciparum on Hainan island de-
creased from 84.2% in 1981 to 40% in 1991 after the official
cessation of chloroquine usage on the island in 1979 (23). A
recent study in Vietnam also demonstrated a similar trend
after chloroquine was replaced with artemisinin derivatives
(33). Loss of fitness in resistant parasites could be one of the
reasons for these declines. This presents a possibility that an
antimalarial drug may be reintroduced after the drug usage has
ceased for a number of years and the prevalence of resistant
parasites has decreased. To avoid an immediate reselection of
mutant parasites, the drug should be reintroduced in combi-
nation with another antimalarial drug.
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